Lung cancer (Amsterdam, Netherlands), 2016-09, Vol.99, p.23-30
2016
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer
- Ist Teil von
- Lung cancer (Amsterdam, Netherlands), 2016-09, Vol.99, p.23-30
- Ort / Verlag
- Ireland: Elsevier Ireland Ltd
- Erscheinungsjahr
- 2016
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Highlights • Sonidegib with etoposide/cisplatin in newly diagnosed SCLC patients is safe and effective. • Creatine kinase elevations were noted, similar to other studies evaluating sonidegib. • Genomic characterization of an exceptional responder reveals SOX2 amplification on 3q26.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0169-5002eISSN: 1872-8332DOI: 10.1016/j.lungcan.2016.04.014Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5427482
- Format
- –
- Schlagworte
- Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Biphenyl Compounds - administration & dosage, Biphenyl Compounds - pharmacokinetics, Circulating tumor cells, Cisplatin - administration & dosage, Cisplatin - pharmacokinetics, Etoposide - administration & dosage, Etoposide - pharmacokinetics, Female, Hedgehog inhibitor, Hedgehog pathway, Hedgehog Proteins - antagonists & inhibitors, Hematology, Oncology and Palliative Medicine, Humans, LDE225, Lung Neoplasms - drug therapy, Lung Neoplasms - mortality, Lung Neoplasms - pathology, Male, Maximum Tolerated Dose, Neoplasm Staging, Neoplastic Cells, Circulating, Pulmonary/Respiratory, Pyridines - administration & dosage, Pyridines - pharmacokinetics, Small cell lung cancer, Small Cell Lung Carcinoma - drug therapy, Small Cell Lung Carcinoma - mortality, Small Cell Lung Carcinoma - pathology, SOX2 amplification, Treatment Outcome